N/A
Completed N=18
Dexcom G6 for Total Pancreatectomy With Islet Autotransplantation (TPIAT) Patients
Source: ClinicalTrials.gov NCT05607576 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
May 2025
Primary outcomePrimary: Dexcom G6 Accuracy Post Radiation Exposure by Clark Error Analysis (Zone A and B %) — 806; 1226; 704; 1715 Matched blood glucose readings — p=<0.05
Summary
A single-center prospective trial on the effects of standard of care radiation exposure on the Dexcom G6 continuous glucose monitoring (CGM) device.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dexcom G6 Accuracy Post Radiation Exposure by Clark Error Analysis (Zone A and B %) |
806; 1226; 704; 1715; 1020; 606 | <0.05 sig |
| PRIMARY Post Radiation Dexcom G6 Transmitter Functional Duration by Clark Error Analysis (Zone A and B %) |
2065; 446; 226; 1173; 128; 61 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Planned TPIAT at CCHMC
- Staying in-patient at CCHMC post TPIAT
- Planned to receive a Dexcom G6 CGM
Exclusion Criteria
- Hemo- or peritoneal dialysis
Data sourced from ClinicalTrials.gov (NCT05607576). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.